Qsemble Capital Management LP Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Qsemble Capital Management LP acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 2,489 shares of the biotechnology company’s stock, valued at approximately $311,000.

Several other hedge funds and other institutional investors have also bought and sold shares of SRPT. Farallon Capital Management LLC raised its stake in Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock valued at $57,356,000 after buying an additional 317,277 shares during the period. Rhumbline Advisers increased its holdings in Sarepta Therapeutics by 146.3% in the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock valued at $42,809,000 after buying an additional 160,942 shares during the period. Blair William & Co. IL increased its holdings in Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock valued at $27,537,000 after buying an additional 131,112 shares during the period. Finally, Retirement Systems of Alabama bought a new position in Sarepta Therapeutics in the 2nd quarter valued at about $18,433,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the topic of several recent analyst reports. Citigroup decreased their target price on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $182.00 price target on shares of Sarepta Therapeutics in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $175.77.

Insider Activity at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Price Performance

SRPT opened at $137.94 on Thursday. The firm has a market cap of $13.18 billion, a P/E ratio of 110.35 and a beta of 0.81. The firm has a 50-day moving average of $121.90 and a 200 day moving average of $131.39. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a fifty-two week low of $78.67 and a fifty-two week high of $173.25.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.